This company has been acquired

How has Mike Minogue's remuneration changed compared to Abiomed's earnings?
Date	Total Compensation	Salary	Company Earnings
Sep 30 2022	n/a	n/a	US$267m
Jun 30 2022	n/a	n/a	US$218m
Mar 31 2022	US$13m	US$789k	US$137m
Dec 31 2021	n/a	n/a	US$133m
Sep 30 2021	n/a	n/a	US$149m
Jun 30 2021	n/a	n/a	US$154m
Mar 31 2021	US$15m	US$608k	US$226m
Dec 31 2020	n/a	n/a	US$200m
Sep 30 2020	n/a	n/a	US$208m
Jun 30 2020	n/a	n/a	US$159m
Mar 31 2020	US$17m	US$768k	US$203m
Dec 31 2019	n/a	n/a	US$245m
Sep 30 2019	n/a	n/a	US$221m
Jun 30 2019	n/a	n/a	US$258m
Mar 31 2019	US$19m	US$753k	US$259m
Dec 31 2018	n/a	n/a	US$222m
Sep 30 2018	n/a	n/a	US$190m
Jun 30 2018	n/a	n/a	US$165m
Mar 31 2018	US$10m	US$718k	US$112m
Dec 31 2017	n/a	n/a	US$90m
Sep 30 2017	n/a	n/a	US$92m
Jun 30 2017	n/a	n/a	US$77m
Mar 31 2017	US$12m	US$649k	US$52m
Dec 31 2016	n/a	n/a	US$48m
Sep 30 2016	n/a	n/a	US$43m
Jun 30 2016	n/a	n/a	US$42m
Mar 31 2016	US$19m	US$630k	US$38m

Compensation vs Market: Mike's total compensation ($USD12.67M) is about average for companies of similar size in the US market ($USD12.79M).

Compensation vs Earnings: Mike's compensation has been consistent with company performance over the past year.

CEO

Mike Minogue (55 yo)

18.7yrs

Tenure

US$12,665,992

Compensation

Mr. Michael R. Minogue, also known as Mike, served as Director at Medical Device Innovation Consortium, previously served as its chairman until June 2019. He has been Chief Executive Officer and President...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Michael Minogue	Chairman	18.7yrs	US$12.67m	0.77% $ 133.2m
Todd Trapp	Executive VP & CFO	4.7yrs	US$3.04m	0.017% $ 2.9m
Marc Began	Executive VP	4.5yrs	US$2.57m	0.027% $ 4.7m
Andrew Greenfield	Executive VP & Chief Commercial Officer	2.7yrs	US$2.84m	0.045% $ 7.8m
David Weber	Scientific & Technology Advisor	less than a year	US$2.29m	0.30% $ 52.2m
Matthew Plano	Executive Vice President of Global Operations & Integration	no data	no data	0.017% $ 3.0m
Thorsten Siess	Executive VP & Chief Technology Officer	no data	no data	no data
Ingrid Ward	Director of Investor Relations	8.3yrs	no data	no data
Sarah Karr	Communications Manager	no data	no data	no data
Michael Howley	VP & GM of Global Sales	13.8yrs	US$1.71m	no data
Karen Mahoney	VP & Chief Human Resources Officer	3.3yrs	no data	no data
Charles Simonton	Executive VP & Chief Medical Officer	2.5yrs	no data	no data

4.5yrs

Average Tenure

55yo

Average Age

Experienced Management: ABMD's management team is considered experienced (4.5 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Michael Minogue	Chairman	18.7yrs	US$12.67m	0.77% $ 133.2m
Martin Sutter	Independent Director	14.6yrs	US$266.80k	0.26% $ 45.2m
Jeannine Rivet	Independent Director	6.8yrs	US$266.80k	0.021% $ 3.5m
Paul Thomas	Independent Director	11.6yrs	US$269.30k	0.013% $ 2.2m
Eric Rose	Independent Director	8.3yrs	US$259.30k	0.032% $ 5.5m
Dorothy Puhy	Independent Lead Director	19.3yrs	US$299.30k	0.032% $ 5.4m
Paula Johnson	Independent Director	1.7yrs	US$499.89k	0.0011% $ 190.8k
Christopher Van Gorder	Independent Director	6.8yrs	US$264.30k	0.015% $ 2.6m
Myron Rolle	Independent Director	1.8yrs	US$259.30k	0.0011% $ 195.9k

8.3yrs

Average Tenure

67yo

Average Age

Experienced Board: ABMD's board of directors are considered experienced (8.3 years average tenure).

This company has been acquired

Abiomed Management

Management criteria checks 4/4

Key information

Recent management updates

Independent Director notifies of intention to sell stock

Executive VP notifies of intention to sell stock

Independent Director notifies of intention to sell stock

Abiomed, Inc., Annual General Meeting, Aug 10, 2022

Abiomed, Inc. Announces Retirement of David Weber as Senior Vice President, Chief Operating Officer

Independent Director recently sold US$1.2m worth of stock

Recent updates

Johnson & Johnson (NYSE:JNJ) completed the acquisition of Abiomed, Inc. (NasdaqGS:ABMD).

Abiomed Announces United States Food and Drug Administration Approves Version of Impella ECP

Abiomed, Inc.(NasdaqGS:ABMD) dropped from FTSE All-World Index (USD)

Abiomed, Inc. Announces First Patients in the World Treated with Impella Rp Flex with Smartassist

Price target increased to US$362

Independent Director notifies of intention to sell stock

Executive VP notifies of intention to sell stock

Independent Director notifies of intention to sell stock

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Johnson & Johnson (NYSE:JNJ) entered into a definitive agreement to acquire Abiomed, Inc. (NasdaqGS:ABMD) for $17.4 billion.

Impella RP Flex with SmartAssist Receives FDA Approval to Treat Right Heart Failure

Abiomed (NASDAQ:ABMD) Has More To Do To Multiply In Value Going Forward

Abiomed, Inc. Successfully Completes All Impella Post-Approval Studies for High-Risk PCI, Cardiogenic Shock, Post-Cardiotomy Cardiogenic Shock and Right Heart Failure

The United States Food and Drug Administration Grants 510(k) Clearance for Impella Low Profile Sheath

Abiomed's Impella low profile sheath gets FDA clearance

Abiomed, Inc. to Report Q2, 2023 Results on Nov 01, 2022

Price target decreased to US$313

Abiomed: Correction Offers Good Buying Opportunity

Abiomed Announces Two Approvals from the U.S. Food and Drug Administration Related to Clinical Research of Impella Heart Pumps in Acute Myocardial Infarction Cardiogenic Shock Patients

U.S. FDA gives two approvals to Abiomed Impella heart pumps

What Does Abiomed, Inc.'s (NASDAQ:ABMD) Share Price Indicate?

Abiomed Announces Restore EF Study Shows Heart Function, Symptom Improvements for High-Risk PCI Patients Supported by Impella

First quarter 2023 earnings: EPS exceeds analyst expectations

Abiomed, Inc. (NasdaqGS:ABMD) announces an Equity Buyback for $200 million worth of its shares.

Price target decreased to US$319

Abiomed FQ1 2023 Earnings Preview

Abiomed, Inc. to Report Q1, 2023 Results on Aug 04, 2022

Returns On Capital At Abiomed (NASDAQ:ABMD) Have Stalled

Abiomed, Inc., Annual General Meeting, Aug 10, 2022

Abiomed's Profit Growth Slows On R&D, Sales Hold Strong Despite Shortages

Full year 2022 earnings: EPS exceeds analyst expectations

Abiomed, Inc. to Report Q4, 2022 Results on Apr 28, 2022

Abiomed, Inc. Announces Retirement of David Weber as Senior Vice President, Chief Operating Officer

Is Abiomed (NASDAQ:ABMD) A Risky Investment?

Independent Director recently sold US$1.2m worth of stock

Senior VP & COO exercised options and sold US$3.1m worth of stock

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Abiomed, Inc. Revises Revenue Guidance for the Fiscal Year 2022

Consensus forecasts updated

Abiomed's Less Troubled 2020 Justifies Multiple, But Medium-Term Headwinds Mean Capital Risk

Early Feasibility Study Demonstrates Successful Use of Abiomed’s preCARDIA Technology

Abiomed, Inc. Announces Regulators Grants Approvals for Impella Surgical Products

The Returns At Abiomed (NASDAQ:ABMD) Aren't Growing

These 4 Measures Indicate That Abiomed (NASDAQ:ABMD) Is Using Debt Safely

Abiomed, Inc. (NasdaqGS:ABMD) agreed to acquire all the assets and business from Sensera, Inc. for $7.5 million.

Independent Director recently sold US$5.1m worth of stock

Second quarter 2022 earnings released: EPS US$1.25 (vs US$1.38 in 2Q 2021)

Abiomed: Impella Will Continue To Drive Revenue Growth

Here's What To Make Of Abiomed's (NASDAQ:ABMD) Decelerating Rates Of Return

Independent Director notifies of intention to sell stock

Consensus forecasts updated

Chairman exercised options and sold US$8.0m worth of stock

First quarter 2022 earnings released: EPS US$1.38 (vs US$0.99 in 1Q 2021)

Abiomed: Recovery Mode Has Been Activated - Reiterate Buy Rating

At US$335, Is It Time To Put Abiomed, Inc. (NASDAQ:ABMD) On Your Watch List?

Abiomed’s Receives U.S. Food and Drug Administration Pre-Market Approval as Safe and Effective to Treat Acute Right Heart Failure for Up to 14 Days

Chairman exercised options and sold US$7.6m worth of stock

DSMB recommends Abiomed trial for heart pump in cardiogenic shock continue

Abiomed, Inc. (NasdaqGS:ABMD) acquired Precardia Inc.

Abiomed acquires preCARDIA a company targeting acute heart failure

Full year 2021 earnings released: EPS US$5.00 (vs US$4.49 in FY 2020)

Here's Why I Think Abiomed (NASDAQ:ABMD) Might Deserve Your Attention Today

Senior VP & COO exercised options and sold US$3.7m worth of stock

Boston Scientific’s new clinical trial can impact Abiomed: Raymond James

Full year 2021 earnings released: EPS US$5.00 (vs US$4.49 in FY 2020)

Abiomed, Inc. Provides Earnings Guidance for the Fiscal Year 2022

Abiomed FQ4 2021 Earnings Preview

Should You Investigate Abiomed, Inc. (NASDAQ:ABMD) At US$315?